Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
By Elana Gotkine HealthDay Reporter
MONDAY, March 10, 2025 -- For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use, according to a research letter published online March 6 in JAMA Network Open.
Omer S. Ashruf, from Northeast Ohio Medical University in Rootstown, and colleagues conducted a retrospective cohort study to compare the risks for hematologic cancers in patients with T2D treated with a GLP-1 RA versus metformin and insulin. The study included patients with T2D prescribed a GLP-1 RA, insulin, or metformin between April 30, 2005, and Oct. 31, 2023 (51,617; 611,115; and 938,602 patients, respectively). Groups were independently matched using a nearest neighbor greedy matching algorithm; 47,716 patients were included in the GLP-1 RA-insulin analysis and 50,590 were included in the GLP-1 RA-metformin analysis.
The researchers found that GLP-1 RA use was associated with significantly lower risks for of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) compared with metformin (hazard ratios, 0.61 and 0.67, respectively). No significant difference was seen in the risk for any other hematologic cancer. GLP-1 RA use was associated with significantly lower risks for myeloid leukemia, lymphoid leukemia, non-Hodgkin lymphoma, MDS, MPN, monoclonal gammopathy, multiple myeloma, and amyloidosis compared with insulin (hazard ratios, 0.39, 0.45, 0.42, 0.19, 0.50, 0.68, 0.49, and 0.52, respectively). GLP-1 RA use was associated with a 54 percent lower risk than that seen with insulin across all hematologic cancers.
"The findings of this cohort study suggest that GLP-1 RAs are associated with reduced risk of developing several hematologic cancers, particularly MDS and MPN, in patients with T2D," the authors write.
One author disclosed ties to Celegene, BMS, and Carobou.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Uterine Cancer Incidence, Mortality Expected to Increase Through 2050
TUESDAY, July 8, 2025 -- Uterine cancer incidence and mortality rates are projected to increase significantly through 2050, according to a study published online July 1...
Planned C-Section May Be Tied to Increased Risk for Leukemia in Offspring
MONDAY, July 7, 2025 -- Children born by planned cesarean section (CS) may have an elevated risk for acute lymphoblastic leukemia (ALL), which is driven by B-cell precursor ALL...
Higher Cardiac Marker Levels Tied to Long-Term Cancer Risk
TUESDAY, July 1, 2025 -- Slightly higher levels of cardiac biomarkers may predict an increased risk for incident cancer, according to a study published online in the July issue of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.